American Society of Hirudotherapy

Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: A novel anticoagulation protocol.

Research article published in Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2016)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsNelson et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2016

Abstract

BACKGROUND: Hypercoagulable conditions are often considered relative contraindications to free flap reconstruction. This paper presents and critically examines a novel anticoagulation regimen developed to address this disease state. METHODS: Hypercoagulable patients who underwent free tissue transfer between 2007 and 2015 were identified. From 2011, all such patients were subjected to a novel anticoagulation protocol involving an intravenous bolus of 2000 U of unfractionated heparin prior to microvascular pedicle anastomosis, followed by a heparin infusion at 500 U/h, which was postoperatively increased to therapeutic levels. Patients were discharged on full anticoagulation for 1 month. Patients prior to 2011 received only subcutaneous heparin. Outcomes in patients receiving this novel anticoagulation protocol were compared to those of patients receiving standard therapy (postoperative subcutaneous heparin). RESULTS: Twenty-three hypercoagulable patients underwent reconstruction with 32 flaps. Eleven patients were administered the novel protocol. No thromboses were noted in the novel protocol cohort, while three thrombotic events occurred in the control cohort (0% vs. 17.6%, p = 0.23). No flaps were salvaged after thrombosis. All losses occurred in the control cohort (0% vs. 17.6%, p = 0.23). The novel protocol cohort was more likely to have postoperative red blood cell transfusions (72.6% vs. 16.7%, p = 0.007), hematomas (26.7% vs. 0%, p = 0.04), and lower mean hemoglobin nadirs [6.9 (1.0) vs. 8.9 ± 1.8 g/dL, p = 0.01]. CONCLUSION: The key approach to hypercoagulable patients is likely prevention over treatment. Patients who received prophylactic heparin infusions had clinically lower rates of thrombotic events and flap loss. However, this encouraging finding must be balanced with the increased risk for postoperative bleeding complications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnticoagulantsDrug Administration ScheduleFemaleFree Tissue FlapsHeparinHumansInfusions, IntravenousMaleMicrosurgeryMiddle AgedPostoperative ComplicationsRetrospective Studies

Summary

Hypercoagulable conditions are often considered relative contraindications to free flap reconstruction. This paper presents and critically examines a novel anticoagulation regimen developed to address this disease state.

Why This Matters for Hirudotherapy

This article examines a novel systemic anticoagulation protocol utilizing intravenous unfractionated heparin to prevent thrombosis in hypercoagulable patients undergoing free tissue transfer (microsurgery). While the novel protocol showed lower thrombotic event rates compared to standard subcutaneous heparin, it was associated with significantly higher risks of bleeding complications, including hematomas and transfusions. For hirudotherapy, this study is clinically relevant because microvascular free flap reconstruction is a primary setting where medicinal leeches are deployed to salvage venous-congested tissue. Understanding the systemic risks of surgical anticoagulation provides a stark contrast to the localized anticoagulant effects of leech therapy. However, this study has no direct link to leeches, evaluating exclusively systemic heparin protocols without mentioning the leech secretome or hirudotherapy.

Citation

Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: A novel anticoagulation protocol.

Nelson et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2016

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.